Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1 in patients with advanced malignancies: Safety and proof of mechanism.

Martijn P. Lolkema, Sarah P. Blagden, E. Jansen et al.|Journal of Clinical Oncology|2019

Cited by 1